Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes

2019 ◽  
Vol 205 ◽  
pp. 77-91 ◽  
Author(s):  
Lydia Giannopoulou ◽  
Martha Zavridou ◽  
Sabine Kasimir-Bauer ◽  
Evi S. Lianidou
Keyword(s):  
Ovarian Cancer ◽  
Liquid Biopsy ◽  
Circulating Mirnas

Potential clinical applications of circulating cell-free DNA in ovarian cancer patients

2018 ◽  
Vol 20 ◽  
Author(s):  
Ana Barbosa ◽  
Ana Peixoto ◽  
Pedro Pinto ◽  
Manuela Pinheiro ◽  
Manuel R. Teixeira
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Liquid Biopsy ◽  
Clinical Applications ◽  
Epigenetic Alterations ◽  
Cell Free Dna ◽  
Non Invasive ◽  
Free Dna ◽  
Potential Use ◽  
Circulating Cell Free Dna

AbstractCirculating cell-free DNA (cfDNA) consists of small fragments of DNA that circulate freely in the bloodstream. In cancer patients, a fraction of cfDNA is derived from tumour cells, therefore containing the same genetic and epigenetic alterations, and is termed circulating cell-free tumour DNA. The potential use of cfDNA, the so-called ‘liquid biopsy’, as a non-invasive cancer biomarker has recently received a lot of attention. The present review will focus on studies concerning the potential clinical applications of cfDNA in ovarian cancer patients.

scholarly journals LIQUID BIOPSY FOR DIAGNOSING OVARIAN CANCER- QUANTIFICATION OF CELL-FREE DNA AND P53 MUTATIONAL ANALYSIS

2020 ◽  
Author(s):  
Shalini Rajaram ◽  
Aanchal Varma ◽  
Rajarshi Kar ◽  
Vinod Kumar Arora ◽  
Bindiya gupta ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Liquid Biopsy ◽  
Mutational Analysis ◽  
Cell Free Dna ◽  
Free Dna

scholarly journals Association of Soluble B7-H4 and Circulating Tumor Cells in Blood of Advanced Epithelial Ovarian Cancer Patients

2021 ◽  
Vol 11 ◽  
Author(s):  
Pawel Mach ◽  
Rainer Kimmig ◽  
Sabine Kasimir-Bauer ◽  
Paul Buderath
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Survival Data ◽  
Liquid Biopsy ◽  
Therapy Response ◽  
Predictive Biomarkers ◽  
Prognostic Biomarkers ◽  
Immune Checkpoints

IntroductionEpithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy worldwide. Reliable predictive biomarkers are urgently needed to estimate the risk of relapse and to improve treatment management. Soluble immune-checkpoints in EOC are promising molecules serving as prognostic biomarkers accessible via liquid biopsy. We thus, aimed at elucidating the role of sB7-H4 in EOC.Material and MethodsWe analyzed soluble serum B7-H4 (sB7-H4) using ELISA and circulating tumor cells (CTCs) in blood applying the AdnaTest OvarianCancer in 85 patients suffering from advanced EOC. Findings were correlated with clinical parameters as well as survival data.ResultssB7-H4 was detectable in 14.1% patients, CTCs in 32.9% patients and simultaneous presence of CTCs and sB7-H4 was found in 7% patients, respectively. Although no association between sB7-H4 and CTC could be documented, each of them served as independent predictive factors for overall survival (OS).ConclusionsB7-H4 and CTCs are independent prognostic biomarkers for impaired survival in EOC. As they are easily accessible via liquid biopsy, they may be of potential benefit for the prediction of therapy response and survival for EOC patients.

scholarly journals Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision

Biomedicines ◽  
2021 ◽  
Vol 9 (10) ◽  
pp. 1316
Author(s):  
Gloria Ravegnini ◽  
Pierandrea De Iaco ◽  
Francesca Gorini ◽  
Giulia Dondi ◽  
Isabella Klooster ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Biological Fluids ◽  
Delayed Diagnosis ◽  
Screening Tests ◽  
Ca 125 ◽  
Circulating Mirnas ◽  
Systematic Revision ◽  
Oncological Patient ◽  
Relapsed Disease

Epithelial ovarian cancer (EOC) is one of the most lethal cancers worldwide, mostly due to nonspecific symptoms and a lack of screening tests, which, taken together, contribute to delayed diagnosis and treatment. The current clinical biomarker is serum CA-125, which allows the identification of most advanced primary and relapsed disease and correlates with disease burden; however, as well highlighted in the literature, CA-125 often lacks sensitivity and specificity, and is not helpful in monitoring chemotherapeutic response or in predicting the risk of relapse. Given that, the identification of novel biomarkers able to foster more precise medical approaches and the personalization of patient management represents an unmet clinical requirement. In this context, circulating miRNAs may represent an interesting opportunity as they can be easily detected in all biological fluids. This is particularly relevant when looking for non-invasive approaches that can be repeated over time, with no pain and stress for the oncological patient. Given that, the present review aims to describe the circulating miRNAs currently identified as associated with therapeutic treatments in OC and presents a complete overview of the available evidence.

Circulating mirnas in a low-volume disease murine model of mutated high-grade serous ovarian cancer

2019 ◽  
Vol 154 ◽  
pp. 52
Author(s):  
A.A. Gockley ◽  
S. Fiascone ◽  
K. Hasselblatt ◽  
W. Fendler ◽  
R.S. Berkowitz ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Murine Model ◽  
High Grade ◽  
Serous Ovarian Cancer ◽  
Circulating Mirnas ◽  
Low Volume

Serum calretinin as a predictor for recurrence and overall survival in ovarian cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17033-e17033
Author(s):  
Pauline Wimberger ◽  
Simon Passek ◽  
Theresa Link ◽  
Yana Vassileva ◽  
Michael Kramer ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Liquid Biopsy ◽  
Calcium Binding ◽  
Tumor Resection ◽  
High Volume ◽  
Primary Diagnosis ◽  
Platinum Resistance ◽  
Serum Samples ◽  
Platinum Based Chemotherapy

e17033 Background: Calretinin (CRT) is a calcium-binding protein, controlling intracellular calcium signaling. Besides its prominent expression in neurons, CRT has diagnostic implications in cancer, particularly in mesothelioma. In a recent liquid biopsy approach, plasma CRT level has been suggested for pre-diagnostic detection of mesothelioma. CRT is also expressed in serous ovarian cancer in about 23% of cases; however, clinical relevance of serum CRT is completely unknown and shall therefore be analyzed, herein. Methods: Serum calretinin (sCRT) was determined by calretinin enzyme-linked immunoabsorbent assay (DLD-Diagnostika GmbH, Hamburg) in a total of 380 serum samples from 134 ovarian cancer patients (thereof n = 115 (86%) with FIGO III or IV), including samples at primary diagnosis and at 4 follow-up reading points in the course of adjuvant treatment. Results: sCRT levels were significantly increased in ovarian cancer patients compared to healthy controls (ED = 0.3ng/ml, p < 0.001) and enabled an accurate discrimination between ovarian cancer and controls (AUC = 0.85). High sCRT levels at primary diagnosis predicted suboptimal debulking surgery without achieving macroscopically complete tumor resection (p < 0.001) and were associated with advanced FIGO-stage (p < 0.001) and high volume of ascites (p < 0.001). Increased sCRT levels at primary diagnosis were an independent predictor of poor PFS (HR:1.99, p = 0.018) and also indicated poor OS (HR:2.49, p = 0.008). Increased sCRT levels before and after platinum-based chemotherapy were independent predictors of poor OS (HR:15.4, p = 0.01; HR:5.59, p = 0.026). Moreover, elevated sCRT levels at primary diagnosis indicated platinum-resistance (p = 0.002). Conclusions: This is the first study, suggesting sCRT as an innovative liquid biopsy marker for ovarian cancer by showing its independent prognostic relevance and its association with primary platinum-resistance.

Sign in / Sign up

Export Citation Format

Share Document